Document Detail

The increasing necessity for market-based pharmaceutical prices.
MedLine Citation:
PMID:  11151309     Owner:  NLM     Status:  MEDLINE    
In most markets, research and development are driven by expected prices, and those prices are determined mainly by consumer willingness to pay for the potential benefits of new products. In the pharmaceutical market, however, the dominant role of government and tax-induced insurance has tended to create a wedge between expected prices and consumer willingness to pay to cure or prevent disease. This distorts investment decisions, tending to cause underinvestment. Recent developments have expanded this gap. The greatly enhanced efficiency of pharmaceutical research has permitted the development of products that provide long term prevention and quality-of-life improvements. While some of these new products can delay or obviate chronic conditions of old age, they do not necessarily reduce healthcare costs (at least not in the short or medium run). Most of the massive benefits of the new research streams are therefore pure consumer benefits, with little benefit for the acute care activities that are the core functions of European and American healthcare delivery or payment systems. These new products are very expensive, despite increased research efficiency, because that efficiency has permitted the industry to address difficult problems that had previously been impervious to solution. To serve consumers well, healthcare providers would have to increase expenditures and prices or taxes to cover these added pharmaceutical costs. But the new products are likely to be perceived mainly as cost increases. The effect is that healthcare entities will become less suited to serve as agents for consumers. One reason is that the most natural, reliable and widely used metrics for evaluating new drugs--healthcare savings and acute care improvements--will be increasingly irrelevant. The implication is that, to a much greater extent than in the past, only market-determined prices can provide adequate signals for future pharmaceutical research investment. The failure to use market prices could deprive consumers of very large future benefits.
J E Calfee
Related Documents :
11066649 - Healthcare applications of knowledge discovery in databases.
17692179 - New and old directions.
17999619 - What is telemedicine? a collection of 104 peer-reviewed perspectives and theoretical un...
8931239 - Medical and dental technology assessment.
19282049 - Patients and the public: knowledge, sources of information and perceptions about health...
11151309 - The increasing necessity for market-based pharmaceutical prices.
19952369 - Science signaling podcast: 1 december 2009.
15061539 - Medical research networks--an international comparison.
21040029 - Models to enhance research capacity and capability in clinical nurses: a narrative review.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  PharmacoEconomics     Volume:  18 Suppl 1     ISSN:  1170-7690     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  2000  
Date Detail:
Created Date:  2001-01-09     Completed Date:  2001-02-01     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  47-57     Citation Subset:  T    
American Enterprise Institute, 1150 17th Street, NW, Washington, DC 20036, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Costs*
Drug Industry / economics*
Economics, Pharmaceutical*
Marketing of Health Services
Prescription Fees
Research / economics,  trends

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is there a link between pharmaceutical consumption and improved health in OECD countries?
Next Document:  Reimbursement for new health technologies. Breakthrough pharmaceuticals as a 20th century challenge.